Antares Pharma Inc. (NASDAQ:ATRS)’s shares plunged more than 4% in last trading hours after it declared Q4 loss increased as the drug developer spent a lot to prepare its possible rheumatoid arthritis treatment Otrexup for narrow appraisal.
The Ewing, N.J., firm declared on Wednesday that it lost $5M, or 4 cents a share, in the quarter that ended Dec. 31. That evaluates to a loss of $154,000, or lowers than 1 cent a share, in the final quarter of 2011, at what time it had fewer shares outstanding. Revenue rose around 1% to $5.5M.
Analysts anticipated, on average, a loss of 3 cents a share on $5.3M in revenue, according to FactSet.
Antares lost $11.4M, or 10 cents a share for the full year, on $22.6M in revenue.
The firm reported that it ended the year with $85.2M in cash and investments and no debt.
Antares Pharma Inc (NASDAQ:ATRS) stock hit highest price at $3.62, beginning with a price of $3.59 and reported decreased -4.17% to the closed at $3.45 with day range of $3.43-$3.62. The total market capitalization remained $431.75 million, total volume held in the session was 1.14 million shares surprisingly higher than its average volume of 859,319 shares.
To check the Stocks ups and downs, ATRS last week stock price volatility remained 4.70% and month was at 4.16%. ATRS generated revenue of 22.50 million in the following twelve months income of -$6.57 million. The Company showed a negative -29.20% in the net profit margin and in addition to in its operating margin which remained -29.19%. Company’s annual sales growth for the past five year was 30.99%.
The ATRS past twelve months price to sales ratio was 19.19 and price to cash ratio remained 14.29. As far as if notice on other major contributors of similar sectors have sale ratio and price to cash ratio remained MELA Sciences Inc (NASDAQ:MELA)’s P/S 172.16% P/C 6.13%, Becton, Dickinson and Co. (NYSE:BDX)’s P/S 2.27% P/C 7.03%, Covidien plc (NYSE:COV)’s P/S 2.59% P/C 22.28%, HeartWare International Inc (NASDAQ:HTWR)’s P/S 11.75% P/C 12.68%.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here